BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20798232)

  • 1. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
    Nojiri S; Gemba K; Aoe K; Kato K; Yamaguchi T; Sato T; Kubota K; Kishimoto T
    Jpn J Clin Oncol; 2011 Jan; 41(1):32-9. PubMed ID: 20798232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for 100 patients with malignant pleural mesothelioma.
    Gonlugur U; Gonlugur TE
    Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M; Strano S; Dechartres A; Jouni R; Triponez F; Chouaid C; Forgez P; Damotte D; Roche N; Régnard JF; Alifano M
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1305-11. PubMed ID: 23072703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
    Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
    Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
    Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
    Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
    Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
    Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.
    de Perrot M; McRae K; Anraku M; Karkouti K; Waddell TK; Pierre AF; Darling G; Keshavjee S; Johnston MR
    Ann Thorac Surg; 2008 Apr; 85(4):1206-10. PubMed ID: 18355497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival in malignant pleural mesothelioma.
    Van Gelder T; Damhuis RA; Hoogsteden HC
    Eur Respir J; 1994 Jun; 7(6):1035-8. PubMed ID: 7925870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
    Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
    Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
    Ghanim B; Hoda MA; Winter MP; Klikovits T; Alimohammadi A; Hegedus B; Dome B; Grusch M; Arns M; Schenk P; Pohl W; Zielinski C; Filipits M; Klepetko W; Berger W
    Ann Surg; 2012 Aug; 256(2):357-62. PubMed ID: 22750759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.
    Motta AB; Pinheiro G; Antonângelo L; Parra ER; Monteiro MM; Pereira JC; Takagaki T; Terra Filho M; Martins S; Capelozzi VL
    J Bras Pneumol; 2006; 32(4):322-32. PubMed ID: 17268732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
    Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
    J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Richards WG; Sugarbaker DJ
    Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
    Tanrikulu AC; Abakay A; Kaplan MA; Küçüköner M; Palanci Y; Evliyaoglu O; Sezgi C; Sen H; Carkanat Aİ; Kirbas G
    Respiration; 2010; 80(6):480-7. PubMed ID: 20881372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
    Kao SC; Pavlakis N; Harvie R; Vardy JL; Boyer MJ; van Zandwijk N; Clarke SJ
    Clin Cancer Res; 2010 Dec; 16(23):5805-13. PubMed ID: 20956618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
    Arrossi AV; Lin E; Rice D; Moran CA
    Am J Clin Pathol; 2008 Nov; 130(5):754-64. PubMed ID: 18854268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant pleural mesothelioma: surgical management in 285 patients.
    Schipper PH; Nichols FC; Thomse KM; Deschamps C; Cassivi SD; Allen MS; Pairolero PC
    Ann Thorac Surg; 2008 Jan; 85(1):257-64; discussion 264. PubMed ID: 18154820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
    Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
    Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.